Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.

J Clin Oncol · 2021 · PMC8177881 · PMID 33356418

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

Although the addition of a fourth course significantly reduced the cumulative incidence of relapse (CIR) and RFS, the OS difference at 5 years failed to reach significance.

also in 4,113 other papers

a strong trendno p-value reported

In terms of OS, based on the number of patients assessable, there is a strong trend for benefit in the recipients of Ara-C, but not for the recipients of MACE/MidAc.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.